COVID 19, emphysema, and secondary pulmonary fibrosis : about a case report

View/ Open
Date
2022-03-01Corporate Author(s)
Pontificia Universidad Javeriana. Facultad de Medicina. Departamento de Ciencias Fisiológicas
Type
Artículo de revista
ISSN
2148-3620 / 2148-5402 (Electrónico)
COAR
InformesShare this record
Citación
Metadata
Show full item record
PDF documents
Abstract
Associations have been drawn between pre-existing diseases and adverse outcomes during the course of the ongoing coronavirus 2019 (COVID-19) pandemic, the disease resulting from infection with recently identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients who have chronic obstructive pulmonary disease with the emphysema-hyperinflated phenotype are one of the population groups with basal risk comorbidities who may have a higher probability of developing secondary pulmonary fibrosis, even in the early stages of COVID-19, potentially leading to permanent adverse functional consequences and even death. The aim of this report was to investigate this pathophysiological association in order to examine potential therapeutic targets for use during the COVID-19 pandemic that could reduce future sequelae using an illustrative clinical case and the available literature.
Community
Pacientes con COVID-19Link to the resource
https://eurasianjpulmonol.com/article/176Source
Eurasian Journal of Pulmonology; Volumen 24 Número 1 , Páginas 65 - 72 (2022)
Google Analytics Statistics
Collections
- Artículos [28]